Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273299 · ClinicalTrials.gov registry record · Phase 3
Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 607
- Enrollment target
NCT00273299 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 607 participants.
The verdict
NCT00273299, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 607 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.
Interventions
- DRUG valsartan plus hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00273299
The ClinicalTrials.gov registry entry for NCT00273299 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 607 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan plus hydrochlorothiazide is the first listed.
NCT00273299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00273299 about?
NCT00273299 is a clinical study titled "Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension". The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared ...
What is the current status of trial NCT00273299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 607 participants. The study started on 2005-11. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00273299?
The interventions under investigation include: valsartan plus hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00273299?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.